【摘要】 目的探讨肺腺癌患者Tau表达水平与多西紫杉醇化疗敏感性及疾病进展时间的关系。方法选择我院66例IIIb/IV期肺腺癌患者,所有患者均采用免疫组化方法检测Tau蛋白的表达水平,按照Tau蛋白的表达水平分为Tau低表达组与高表达组,两组分别应用多西紫杉醇+顺铂化疗,疾病控制者4疗程化疗后单药多西紫杉醇维持化疗直至进展,比较两组的近期疾病控制率及疾病进展时间。结果 66例患者中Tau低表达者41例,低表达率为62.12%。Tau低表达组与高表达组的近期疾病控制率分别为80.49%与56.00%,二组相比有显著差异(χ~2=4.284,P<0.05)。Tau低表达组的中位疾病进展时间亦优于高表达组,分别为5.6月与4.1月,两者相比有显著差异(χ~2=4.909,P<0.05)。结论 Tau低表达的肺腺癌患者应用含多西紫杉醇的方案化疗,具有更高的疾病控制率与更优的疾病控制时间,临床可通过检测Tau蛋白表达水平来预测对多西紫杉醇的化疗敏感性。更多还原

【Abstract】 Objective To investigate the relationship of the level of Tau expression in patients with pulmonary adenocarcinoma with the sensitivity of docetaxel therapy and time to tumor progression(TTP). Methods 66 patients with stage IIIb/IV pulmonary adenocarcinoma were enrolled in our study. The expression of Tau protein in pulmonary cancer was detected by immunohistochemical methods. According to the expression level of Tau protein, the patients were divided into the Tau low expression group and the high expression group. The two groups were treated with docetaxel plus cisplatin, and the disease control group was given docetaxel maintenance therapy until the disease progressed after 4 courses of chemotherapy. The disease control rate and time to tumor progression between the two groups were analyzed. Results The Tau low expression rate was 62.12%(41/66) of all test cases. The recent disease control rates in the Tau low express group was better than the high express group(80.49% vs 56.00%, P<0.05). The median time to tumor progression in the Tau low expression group was 5.6 months, longer than that of the Tau high expression group(4.1 months)(χ2=4.909, P<0.05). Conclusion Chemotherapy combined with docetaxel-based regimen has higher disease control rate and longer time to tumor progression in treatment of lung adenocarcinoma patients with low expression of Tau. The sensitivity of docetaxel can be predicted by detecting the level of Tau protein expression in clinic.更多还原